Idexx (IDXX) Down 7.8% Since Last Earnings Report: Can It Rebound?
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research9/3/2026Negative
IDXX
IDEXX Laboratories IncNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$42.23B
P/E Ratio
37.60
EPS
$14.24
Beta
1.54
52W High
$769.98
52W Low
$518.55
50-Day MA
$558.15
200-Day MA
$607.14
Dividend Yield
—
Profit Margin
25.00%
Forward P/E
31.95
PEG Ratio
2.90
About IDEXX Laboratories Inc
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Fundamentals
| Revenue (TTM) | $4.55B |
| Gross Profit (TTM) | $2.84B |
| EBITDA | $1.62B |
| Operating Margin | 35.00% |
| Return on Equity | 74.20% |
| Return on Assets | 27.10% |
| Revenue/Share (TTM) | $57.17 |
| Book Value | $20.45 |
| Price-to-Book | 25.86 |
| Price-to-Sales (TTM) | 9.26 |
| EV/Revenue | 9.36 |
| EV/EBITDA | 26.35 |
| Quarterly Earnings Growth (YoY) | 17.60% |
| Quarterly Revenue Growth (YoY) | 9.70% |
| Shares Outstanding | $78.88M |
| Float | $78.50M |
| % Insiders | 0.22% |
| % Institutions | 96.81% |
Historical Volatility
HV 10-Day
22.40%
HV 20-Day
26.79%
HV 30-Day
27.71%
HV 60-Day
30.96%
HV Rank
27.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($698.92 target)
4
Strong Buy4
Buy5
Hold1
Strong SellLatest News
Baron Focused Growth Fund Q2 2026 Portfolio Update
Baron Focused Growth Fund rebounded in Q2 from a disappointing start to the year, with the Fund gaining 13.26% compared with a gain of 24.02% for the Russell 2500 Growth Index. We remain steadfast in our commitment to long-term investing in competitively advantaged, growth businesses. As of June 30, 2026, the Fund owned 28 investments.
Seeking Alpha9/3/2026Positive
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am – 11:20 am (ET). A live audio webcast of the fireside chat will be available through.
Business Wire8/31/2026Neutral
Idexx Laboratories (IDXX) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research8/31/2026Positive
Here's Why Idexx Laboratories (IDXX) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research8/24/2026Positive
Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?
IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.
Zacks Investment Research8/21/2026Negative
IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve
IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.
Zacks Investment Research8/20/2026Positive
Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?
IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.
Zacks Investment Research8/19/2026Positive
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript
Seeking Alpha8/18/2026Neutral
IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests
IDEXX Laboratories NASDAQ: IDXX outlined an innovation-led growth strategy at its 2026 Investor Day, highlighting a $45 billion global companion-animal testing opportunity, expanded commercial investments and a pipeline of diagnostic, software and artificial-intelligence offerings intended to increase testing utilization in veterinary practices.
MarketBeat8/14/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IDXX and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026